A randomized phase ii study comparing four different interferon therapies in patients with recalcitrant condyloma acuminata.

被引：0
|
作者：
Trizna, Z
Tyring, SK
机构：
[1] UNIV TEXAS,MED BRANCH,DEPT DERMATOL,GALVESTON,TX 77550
[2] UNIV TEXAS,MED BRANCH,DEPT MICROBIOL & IMMUNOL,GALVESTON,TX 77550
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 1997年 / 108卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [31] HEPATOCELLULAR-CARCINOMA - AN ECOG RANDOMIZED PHASE-II STUDY OF INTERFERON-BETA AND MENAGORIL
    FALKSON, G
    LIPSITZ, S
    BORDEN, E
    SIMSON, I
    HALLER, D
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (04): : 287 - 292
  • [32] A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC).
    Infante, J. R.
    Cohn, A. L.
    Reid, T. R.
    Edenfield, W. J.
    Cescon, T.
    Hamm, J. T.
    Tarazi, J. C. Ed
    Kim, S.
    Rosbrook, B.
    Cartwright, T. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [33] NON-RANDOMIZED PHASE II STUDY COMPARING METRONOMIC REGIMENS OF CHEMOTHERAPY IN PATIENTS (PTS) WITH REFRACTORY METASTATIC COLORECTAL CANCER (MCRC)
    Chubenko, V. A.
    Protsenko, S. A.
    Mikhalychenko, T. D.
    Moiseyenko, F. V.
    Brezhnev, N. V.
    Novik, A. V.
    Volkov, N. M.
    Semenov, I. I.
    Moiseyenko, V. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 181 - 182
  • [34] A phase II study of carboplatin, cisplatin, interferon-α, and tamoxifen for patients with metastatic melanoma
    Gause, BL
    Sharfman, WH
    Janik, JE
    Curti, BD
    Steis, RG
    Urba, WJ
    Smith, JW
    Alvord, WG
    Longo, SL
    CANCER INVESTIGATION, 1998, 16 (06) : 374 - 380
  • [35] Final analysis of a multicenter, randomized phase II trial comparing three different chemoradiotherapy regimens in the treatment of patients with locally advanced, nonmetastatic pancreatic cancer
    Wilkowski, R.
    Boeck, S.
    Ostermaier, S.
    Sauer, R.
    Herbst, M.
    Fietkau, R.
    Flentje, M.
    Bruns, C. J.
    Rau, H. G.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Targeting therapies influence survival of refractory patients with advanced lung adenocarcinoma: A phase II randomized trial.
    Zarogoulidis, K.
    Boutsikou, E.
    Kontakiotis, T.
    Zarogoulidis, P.
    Eleftheriadou, E.
    Sacas, L.
    Galaktidou, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] A RANDOMIZED PHASE-II STUDY COMPARING AMINOGLUTETHIMIDE VS TRILOSTANE VS MPA VS HYDROCORTISONE - AN EORTC STUDY
    ROSE, C
    MOURIDSEN, HT
    WILDIERS, J
    PARIDAENS, R
    SYLVESTER, R
    ROTMENSZ, N
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (06): : 717 - 717
  • [38] A randomized phase II study of pancrelipase in patients with gastrectomy to assess the prevention of weight
    Tamura, S.
    Taniguchi, H.
    Takeno, A.
    Murakami, K.
    Katsura, Y.
    Ohmura, Y.
    Naito, A.
    Kagawa, Y.
    Takeda, Y.
    Kato, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
    Kim, Kevin B.
    Prieto, Victor
    Joseph, Richard W.
    Diwan, Abdul H.
    Gallick, Gary E.
    Papadopoulos, Nicholas E.
    Bedikian, Agop Y.
    Camacho, Luis H.
    Hwu, Patrick
    Ng, Chaan S.
    Wei, Wei
    Johnson, Marcella M.
    Wittemer, Sabine M.
    Vardeleon, Anna
    Reckeweg, Aaron
    Colevas, A. Dimitrios
    MELANOMA RESEARCH, 2012, 22 (04) : 294 - 301
  • [40] LONG TERM FOLLOW UP ON PATIENTS IN THE RANDOMIZED PHASE II PARALLEL STUDY
    Ladenstein, Ruth
    Siabalis, Dimitris
    Poetschger, Ulrike
    De Bernardi, Bruno
    Bergeron, Christoph
    Lewis, Ian
    Stein, Jerry
    Kohler, Janice
    Shaw, Peter
    Holter, Wolfgang
    Michon, Jean
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 810 - 810
12345